Table 3.
Subgroup analysis between non-mechanically ventilated and mechanically ventilated COVID-19 patients who received tocilizumab.
| Parameters | Non-mechanically ventilated (n = 32) | Mechanically ventilated (n = 29) | P value |
|---|---|---|---|
| Continuous variables (median (IQR) | |||
| Age (years) | 49 (44–61) | 52 (42–57) | 0.95 |
| Hemoglobin (g/L) | 13.4 (11.5–14.2) | 12.9 (11.4–14.3) | 0.82 |
| White blood cells (cells/mm3) | 8.25 (6.79–9.41) | 8.32 (6.75–9.5) | 0.64 |
| Platelets (cells/mm3) | 277.4 (186–358.5) | 278.6 (187–354.9) | 0.77 |
| Creatinine (mg/L) | 0.75 (0.5–0.9) | 0.8 (0.5–1.1) | 0.08 |
| C-reactive protein (mg/L) | 30.9 (24–47.6) | 31.3 (30.5–47.5) | 0.14 |
| Onset of symptoms to ICU admission | 5 (3–6) | 5 (4–7) | 0.87 |
| ICU length of stay | 10 (8–16) | 14 (11–20) | 0.04* |
| Hospital length of stay | 11 (8–17) | 16 (13–26 | 0.01* |
| APACHE 4 score | 50 (36.2–69.4) | 56 (38–72) | 0.35 |
| Categorical variables (number, %) | |||
| Males | 27 (84.4%) | 27 (93.1%) | 0.43 |
| Survival on day-14 post admission | 27 (84.4%) | 19 (65.5%) | 0.088 |
| Obesity (body mass index >30) | 3 (9.4%) | 12 (41.4%) | 0.018** |
| More than one comorbidity | 19 (59.4%) | 19 (65.5%) | 0.62 |
| More than one hospital acquired infection | 3 (4.9%) | 9 (14.7%) | 0.01** |
Abbreviations: IQR = interquartile range, ICU = intensive care unit, APACHE 4 score = Acute physiology and chronic health evaluation 4 score *Comparisons with Wilcoxon rank sum test or student's t-test as appropriate; p values < 0.05 were statistically significant; ** Comparisons with Fisher's exact test or chi2 test as appropriate, p values < 0.05 were statistically significant.